Brief: Rezolute Receives Priority Medicines Eligibility From European Medicines Agency For Enhanced Regulatory Support Of RZ358 In Congenital Hyperinsulinism

Rezolute

17/10/2023 13:50

Oct 17 (Reuters) - Rezolute Inc  RZLT.O :
    * REZOLUTE RECEIVES PRIORITY MEDICINES (PRIME) ELIGIBILITY
FROM
EUROPEAN MEDICINES AGENCY FOR ENHANCED REGULATORY SUPPORT OF
RZ358 IN CONGENITAL HYPERINSULINISM
    * REZOLUTE INC: PLAN TO INITIATE OUR PHASE 3 STUDY FOR RZ358
THIS
QUARTER

Source text for Eikon:  ID:nGNXCWxyS 
Further company coverage:  RZLT.O 

 ((Reuters.Briefs@thomsonreuters.com;))